文献速递肾小球疾病

二甲双胍激活AMPK治疗局灶节段性肾小球硬化的2期试验原理与设计

Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis.
PubMed 文献 · Kidney Int Rep · 2024-02-13

本文报告一项2期双盲安慰剂对照随机试验的原理与设计,旨在评估二甲双胍作为附加疗法治疗活检确诊的局灶节段性肾小球硬化(FSGS)的疗效与安全性。计划随机分配30例患者接受二甲双胍或安慰剂(联合标准免疫抑制),研究6个月后与足细胞损伤或耗竭相关的机制生物标志物及结局。

要点

  • FSGS是最常见的导致终末期肾病的原发性肾小球疾病,以足细胞损伤和耗竭为特征。
  • 临床前数据显示二甲双胍激活AMPK可减轻FSGS中的足细胞耗竭和氮质血症。
  • 该2期试验将为二甲双胍作为FSGS附加疗法提供疗效和安全性初步证据。

核心结论

  • 该2期试验将初步揭示二甲双胍作为FSGS附加疗法的潜在疗效和安全性,为设计更大规模3期研究提供关键步骤。

研究设计与样本

  • 2期、双盲、安慰剂对照随机试验,计划随机分配30例活检确诊的FSGS患者接受二甲双胍或安慰剂(联合标准免疫抑制),评估6个月后的结局。

关键数值与推荐

  • 计划随机分配30例活检确诊的FSGS患者,评估6个月后与足细胞损伤或耗竭相关的机制生物标志物及结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Focal segmental glomerulosclerosis (FSGS), the most common primary glomerular disease leading to end-stage kidney disease (ESKD), is characterized by podocyte injury and depletion, whereas minimal change disease (MCD) has better outcomes despite podocyte injury. Identifying mechanisms capable of preventing podocytopenia during injury could transform FSGS to an "MCD-like" state. Preclinical data have reported conversion of an MCD-like injury to one with podocytopenia and FSGS by inhibition of AMP-kinase (AMPK) in podocytes. Conversely, in FSGS, AMPK-activation using metformin (MF) mitigated podocytopenia and azotemia. Observational studies also support beneficial effects of MF on proteinuria and chronic kidney disease (CKD) outcomes in diabetes. A randomized controlled trial (RCT) to test MF in podocyte injury with FSGS has not yet been conducted. METHODS: We report the rationale and design of phase 2, double-blind, placebo-controlled RCT evaluating the efficacy and safety of MF as adjunctive therapy in FSGS. By randomizing 30 patients with biopsy-confirmed FSGS to MF or placebo (along with standard immunosuppression), we will study mechanistic biomarkers that correlate with podocyte injury or depletion and evaluate outcomes after 6 months. We specifically integrate novel urine, blood, and tissue markers as surrogates for FSGS progression along with unbiased profiling strategies. RESULTS AND CONCLUSION: Our phase 2 trial will provide insight into the potential efficacy and safety of MF as adjunctive therapy in FSGS-a crucial step to developing a larger phase 3 study. The mechanistic assays here will guide the design of other FSGS trials and contribute to understanding AMPK activation as a potential therapeutic target in FSGS. By repurposing an inexpensive agent, our results will have implications for FSGS treatment in resource-poor settings.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Barsotti GC, Luciano R, Kumar A, et al. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2024. PMID: 38707807. doi:10.1016/j.ekir.2024.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。